Investigating resistance to anti-estrogen therapy in aggressive breast cancer.
WNT pathway-driven anti-estrogen therapy resistance in breast cancer
This study is looking at a tough type of breast cancer called lumino-basal breast cancer, especially in women under 50, to find out why some treatments that block estrogen don’t work well, with the hope of discovering better ways to help those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11083025 on NIH RePORTER |
What this research studies
This research focuses on a specific type of aggressive breast cancer known as lumino-basal breast cancer (LBBC), which is characterized by a mix of estrogen receptor-positive and negative cells. The study aims to understand how these cancers resist anti-estrogen therapies, particularly in younger women under 50. By examining the role of certain hormones and signaling pathways, the research seeks to identify mechanisms that contribute to therapy resistance. Patients may benefit from insights that could lead to more effective treatment strategies tailored to this aggressive cancer subtype.
Who could benefit from this research
Good fit: Ideal candidates for this research are young women under 50 diagnosed with estrogen receptor-positive lumino-basal breast cancer.
Not a fit: Patients with other types of breast cancer or those who are not estrogen receptor-positive may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with therapy-resistant breast cancer.
How similar studies have performed: Previous research has shown promising results in understanding therapy resistance in breast cancer, but this specific approach targeting LBBC is relatively novel.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rui, Hallgeir — Thomas Jefferson University
- Study coordinator: Rui, Hallgeir
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.